Summary of Study ST002290
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001307. The data can be accessed directly via it's Project DOI: 10.21228/M8S124 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002290 |
| Study Title | Metabolic impact of anticancer drugs Pd2Spermine and Cisplatin on the polar metabolome of brain from cell-derived xenograft mouse model of Triple-Negative Breast Cancer (part 1) |
| Study Type | NMR-based metabolomics |
| Study Summary | Platinum (Pt(II)) drugs, e.g. cisplatin (cDDP), are some of the most used chemotherapeutic agents, yet tumor acquired resistance and high toxicity are still current drawbacks. Palladium (Pd(II))-complexes are alternatives due to similar metal coordination and promising cytotoxic properties. Metabolomics can measure the metabolic response of drug-exposed tissues, unveiling insight into drug mechanisms and new markers of drug efficacy/toxicity. The present 1H NMR metabolomics study aims to characterize the in vivo response of the impact of a Pd(II)-complex with polyamine spermine (Pd2Spm), compared to cDDP, on polar metabolism of brain from cell-derived xenograft mouse model of Triple-Negative Breast Cancer. |
| Institute | University of Aveiro |
| Department | Department of Chemistry and CICECO-Aveiro Institute of Materials |
| Laboratory | Metabolomics from Ana M. Gil |
| Last Name | Carneiro |
| First Name | Tatiana João |
| Address | Campus Universitário de Santiago, Aveiro, Aveiro, 3810-193, Portugal |
| tatiana.joao@ua.pt | |
| Phone | +351926369478 |
| Submit Date | 2022-09-14 |
| Num Groups | 3 |
| Total Subjects | 22 |
| Num Females | 22 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | fid |
| Analysis Type Detail | NMR |
| Release Date | 2022-12-15 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR001307 |
| Project DOI: | doi: 10.21228/M8S124 |
| Project Title: | Biochemical Impact of Platinum and Palladium-based Anticancer Agents – BioIMPACT |
| Project Type: | NMR-based metabolomics |
| Project Summary: | Platinum (Pt(II)) drugs, e.g. cisplatin (cDDP), are some of the most used chemotherapeutic agents, yet tumor acquired resistance and high toxicity are still current drawbacks. Palladium (Pd(II))-complexes are alternatives due to similar metal coordination and promising cytotoxic properties. Metabolomics can measure the metabolic response of drug-exposed tissues, unveiling insight into drug mechanisms and new markers of drug efficacy/toxicity. The present 1H NMR metabolomics study aims to characterize the in vivo response of the impact of a Pd(II)-complex with polyamine spermine (Pd2Spm), compared to cDDP, on the metabolism of several organs from healthy mice. |
| Institute: | University of Aveiro |
| Department: | Department of Chemistry and CICECO-Aveiro Institute of Materials |
| Laboratory: | Metabolomics from Ana M. Gil |
| Last Name: | Carneiro |
| First Name: | Tatiana J. |
| Address: | Campus Universitário de Santiago, Aveiro, Aveiro, 3810-193, Portugal |
| Email: | tatiana.joao@ua.pt |
| Phone: | +351926369478 |
| Funding Source: | This research was developed within the scope of the CICECO—Aveiro Institute of Materials, with references UIDB/50011/2020 and UIDP/50011/2020, financed by national funds through the Por-tuguese Foundation for Science and Technology (FCT/MEC) and when appropriate co-financed by European Regional Development Fund (FEDER) under the PT2020 Partnership Agreement. This work was also funded by the FCT through LAQV/REQUIMTE FCT UIDB/50006/2020 (C.D.), UIDB/00070/2020 (A.L.M.B.d.C and M.P.M.M.), POCI-01-0145-FEDER-0016786, and Cen-tro-01-0145-FEDER-029956 (co-financed by COMPETE 2020, Portugal 2020 and European Com-munity through FEDER). We also acknowledge the Portuguese National NMR Network (PTNMR), supported by FCT funds as the NMR spectrometer used is part of PTNMR and partially supported by Infrastructure Project Nº 022161 (co-financed by FEDER through COMPETE 2020, POCI and PORL, and the FCT through PIDDAC). M.V. thanks the FCT and the PhD Program in Medicines and Pharmaceutical Innovation (i3DU) for his PhD grant PD/BD/135460/2017 and T.J.C. thanks FCT for her PhD grant SFRH/BD/145920/2019; both grants were funded by the European Social Fund of the European Union and national funds FCT/MCTES. |
Subject:
| Subject ID: | SU002376 |
| Subject Type: | Mammal |
| Subject Species: | Mus musculus |
| Taxonomy ID: | 10090 |
| Genotype Strain: | CBA nude (N:NIH(S)II-nu/nu) |
| Age Or Age Range: | 6 to 7-weeks old |
| Gender: | Female |
| Animal Animal Supplier: | i3S Animal Facility (Porto, Portugal) |
| Animal Housing: | ICBAS-UP Rodent Animal House Facility (Porto, Portugal) |
| Animal Light Cycle: | 12h light/dark cycles (7.00 AM lights on) |
| Animal Feed: | ad libitum |
| Animal Water: | ad libitum |
| Animal Inclusion Criteria: | Healthy animails |
| Species Group: | CBA nude (N:NIH(S)II-nu/nu) |
Factors:
Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)
| mb_sample_id | local_sample_id | Treatment_group |
|---|---|---|
| SA220012 | xeno_B_EA_A_24_1_2 | Cisplatin-treated |
| SA220013 | xeno_B_EA_A_16b_1_2 | Cisplatin-treated |
| SA220014 | xeno_B_EA_A_25b_1_2 | Cisplatin-treated |
| SA220015 | xeno_B_EA_A_32b_1_2 | Cisplatin-treated |
| SA220016 | xeno_B_EA_A_33_1_2 | Cisplatin-treated |
| SA220017 | xeno_B_EA_A_14_1_2 | Cisplatin-treated |
| SA220018 | xeno_B_EA_A_28b_1_2 | Cisplatin-treated |
| SA220019 | xeno_B_EA_A_7_1_2 | Cisplatin-treated |
| SA220020 | xeno_B_EA_C_17_1_2 | Control |
| SA220021 | xeno_B_EA_C_20_1_2 | Control |
| SA220022 | xeno_B_EA_C_26_1_2 | Control |
| SA220023 | xeno_B_EA_C_29_1_2 | Control |
| SA220024 | xeno_B_EA_C_27_1_2 | Control |
| SA220025 | xeno_B_EA_C_11_1_2 | Control |
| SA220026 | xeno_B_EA_B_23b_1_2 | Pd2Spm-treated |
| SA220027 | xeno_B_EA_B_30b_1_2 | Pd2Spm-treated |
| SA220028 | xeno_B_EA_B_22b_1_2 | Pd2Spm-treated |
| SA220029 | xeno_B_EA_B_10_1_2 | Pd2Spm-treated |
| SA220030 | xeno_B_EA_B_8_1_2 | Pd2Spm-treated |
| SA220031 | xeno_B_EA_B_13_1_2 | Pd2Spm-treated |
| SA220032 | xeno_B_EA_B_18_1_2 | Pd2Spm-treated |
| SA220033 | xeno_B_EA_B_19_1_2 | Pd2Spm-treated |
| Showing results 1 to 22 of 22 |
Collection:
| Collection ID: | CO002369 |
| Collection Summary: | At day 39 post-implantation of MDA-MB-231 cells (25G needle, 5E6 cells in 150 microliters of PBS) in the left flank of mice, and, at day 9 post-treatment with metal-based drugs, the mice were sacrificed with isoflurane, organs were excised, snap-frozen and stored at -80 ºC. |
| Sample Type: | Brain |
| Collection Duration: | Inferior to one minute |
| Storage Conditions: | -80℃ |
Treatment:
| Treatment ID: | TR002388 |
| Treatment Summary: | At day 25 post-implantation, 8 animals were randomly chosen into three groups to receive the treatment with either (i) vehicle (phosphate-buffered saline, PBS) - controls, (ii) cDDP (2 mg/kg/day), or (iii) Pd2Spm (5 mg/kg/day), via intraperitoneal injection, during five consecutive days. Two control animals were excluded from the study since they developed ulcerated tumors (at day 28 post-implantation) and needed to be prematurely euthanized. |
| Treatment Route: | Intraperitoneal injection |
| Treatment Dosevolume: | 500 microliters |
| Treatment Vehicle: | PBS (phosphate-buffered saline solution) |
Sample Preparation:
| Sampleprep ID: | SP002382 |
| Sampleprep Summary: | The frontal cortex of each mice brain was mechanically grounded in liquid nitrogen and samples were extracted using the biphasic methanol/ chloroform/ water (2:2:1) method. Aqueous phase was recovered and dried. Previously to NMR acquisition, aqueous extracts were suspended in 650 µL of 100 mM sodium phosphate buffer (pH 7.4, in D2O containing 0.25% 3-(trimethylsilyl)-propionic-2,2,3,3-d4 acid (TSP) for chemical shift referencing). Samples were then homogenized and transferred into 5mm NMR tubes. |
| Processing Storage Conditions: | -80℃ |
| Extraction Method: | Biphasic method (methanol/ chloroform/ water) |
| Extract Storage: | -80℃ |
Analysis:
| Analysis ID: | AN003742 |
| Laboratory Name: | Metabolomics Ana M. Gil |
| Analysis Type: | NMR |
| Acquisition Date: | October 2021 |
| Software Version: | Topspin 3.2 |
| Results File: | ST002290_AN003742_Results.txt |
| Units: | ppm |
NMR:
| NMR ID: | NM000249 |
| Analysis ID: | AN003742 |
| Instrument Name: | Avance III TM HD 500MHz |
| Instrument Type: | FT-NMR |
| NMR Experiment Type: | 1D-1H |
| NMR Comments: | 1st subfolder contains raw spectra; 2nd subfolder contains manually processed spectra |
| Field Frequency Lock: | Deuterium |
| Spectrometer Frequency: | 500MHz |
| NMR Probe: | TXI |
| NMR Solvent: | D2O |
| NMR Tube Size: | 5mm |
| Shimming Method: | Topshim |
| Receiver Gain: | 203 |
| Temperature: | 298K |
| Number Of Scans: | 512 |
| Acquisition Time: | 2.34s |
| Relaxation Delay: | 2s |
| Spectral Width: | 7002.801 |
| Zero Filling: | 64k |
| Baseline Correction Method: | Manual |
| Chemical Shift Ref Std: | TSP (3-(trimethylsilyl)-propionic-2,2,3,3-d4 acid) |
| NMR Results File: | BrainAE_NMR_data.txt UNITS:ppm |
